Key Highlights
- Talus Bioscience raises $11.2M in Seed+ funding led by Two Bear Capital.
- Funds to advance programs targeting Brachyury-driven cancers and prostate cancer.
- Expansion of proprietary MARMOT platform for AI-driven discovery of modulators.
Source: Business Wire
Notable Quotes
- “This new funding from our exceptional partners validates and supports our work producing the first AI model to discover and optimize new modulators of any transcription factor.” — Alex Federation, PhD, CEO and Co-Founder at Talus Bioscience
- “The scale, comprehensiveness, and efficiency with which they can target transcription factors gives their AI approach a distinct advantage.” — Avery Sonnenberg, PhD, Principal at Two Bear Capital
SoHC's Take
Talus Bioscience’s recent funding milestone underscores the growing importance of AI in drug discovery, particularly in addressing complex, previously undruggable targets like transcription factors. By leveraging their MARMOT platform, Talus Bio is positioned to dramatically accelerate the identification and optimization of novel therapeutic candidates, potentially transforming treatment paradigms for diseases that have long eluded traditional approaches. The participation of top-tier investors like Two Bear Capital not only validates Talus Bio’s innovative approach but also highlights the broader industry shift towards integrating advanced computational tools with drug discovery.
